|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Daniel Schneider||Pres & CEO||N/D||N/D||N/D|
|Mr. Erik Dahl||Chief Financial Officer||N/D||N/D||1957|
|Mr. David Moskowitz||Head of Investor Relations||N/D||N/D||N/D|
|Ms. Patricia Kelly||VP of Global HR||N/D||N/D||N/D|
|Dr. Anders Neijber||Chief Medical Officer of Global Medical Affairs, Clinical Devel. and R&D||N/D||N/D||N/D|
|Mr. Tolv Hillestad||Group Controller||N/D||N/D||N/D|
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
L'ISS Governance QualityScore di Photocure ASA al 1 gennaio 2023 è 4. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 8.